Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme [Abstract]

Bahl, A. K., Masson, S., Malik, Z., Birtle, A., Sundar, S., Jones, R., James, N., Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869, Kumar, S., Bottomley, D., Lydon, A., Chowdhury, S., Wylie, J. and De Bono, J. 2012. Cabazitaxel for metastatic castration resistant prostate cancer (mCRPC): Interim safety and quality of life (QOL) data from the UK early access programme [Abstract]. European Urology Supplements 11 (1) , e129. 10.1016/S1569-9056(12)60128-6

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Additional Information:	27th Annual Congress of the European Association of Urology – Abstracts
Publisher:	Elsevier
ISSN:	1569-9056
Last Modified:	24 Oct 2022 10:17
URI:	https://orca.cardiff.ac.uk/id/eprint/43758

Actions (repository staff only)

Edit Item